Eam Investors, LLC Viridian Therapeutics, Inc.\De Transaction History

Eam Investors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Jul 12, 2023	SELL	$25.04 - $37.6 $6.53 Million - $9.81 Million	-260,896 Reduced 76.81%	78,763 $2 Million
Q1 2023 May 12, 2023	BUY	$25.04 - $37.6 $6.01 Million - $9.02 Million	240,019 Added 240.89%	339,659 $8.64 Million
Q4 2022 Feb 14, 2023	BUY	$18.78 - $29.74 $862,640 - $1.37 Million	45,934 Added 85.53%	99,640 $2.91 Million
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $574,654 - $1.37 Million	53,706 New	53,706 $1.1 Million

179

76.8M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $839M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.